FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4376611430> ?p ?o ?g. }

• W4376611430 abstract "<p>Supplementary Figure S1. The majority of Pb-Cre; PTENfl/fl Trp53fl/fl mice are de novo resistant to ADT.Supplementary Figure S2. ADT/PI3Ki combination therapy halts prostate tumor growth up to 14 days, followed by development of resistance in majority of Pb-Cre; PTENfl/fl Trp53fl/fl mice.Supplementary Figure S3. PI3Ki treatment with concurrent androgen depletion does not alter proliferation and survival of PTEN/p53-deficient murine PC cells in vitro.Supplementary Figure S4. ADT/PI3K inhibitor combination increases MHC-II and PD-1 expression on TAM within the TME of PTEN/p53-deficient murine PC.Supplementary Figure S5. PD-1 upregulation suppresses phagocytic capacity of activated TAM.Supplementary Figure S6. Ex vivo AD + PI3Ki + PD-1 antibody treatment activates MHCIIlo TAM when co-cultured with PTEN/p53-deficient murine prostate tumor cells.Supplementary Figure S7. The addition of PD-1 blockade to androgen depletion/PI3Ki therapy does not alter phagocytic capacity of PD-1 lo macrophages.Supplementary Figure S8. The combination of androgen depletion, PI3Ki and aPD-1 blockade does not alter phagocytic checkpoint expression on PTEN/p53-deficient prostate tumor cells.Supplementary Figure S9. Androgen depletion, singly and in combination with aPD-1, did not alter phagocytosis activity of inactivated MHC-IIlo/PD-1 lo and MHC-IIlo/PD-1 hi TAM subsets.Supplementary Figure S10. Androgen depletion, not PI3Ki or aPD1, directly enhances TAM activation within the TME of PTEN/p53-deficient PC.Supplementary Figure S11. PI3Ki does not alter phagocytosis/histone lactylation status of MHC-IIlo/PD-1 lo TAM and MHC-IIlo/PD-1 hi TAM.Supplementary Figure S12. PI3Ki inhibits lactate secretion from PTEN/p53-deficient prostate tumor cells within TME.Supplementary Figure S13. Direct ex vivo treatment of TAM with PI3Ki, singly and in combination with PD-1 antibody and/or androgen depletion does not alter their histone lactylation profile.Supplementary Figure S14. ADT + PI3Ki + aPD-1 induces tumor control in 60% of Pb-Cre; PTENfl/fl TP53fl/fl mice.Supplementary Figure S15. Depletion of activated TAM abrogates anti-cancer response elicited by ADT + PI3Ki + PD-1 antibody treatment in the PTEN/p53-deficient murine prostate GEMM tumors.Supplementary Figure S16. Long-term treatment of ADT + PI3Ki + aPD-1 activates Wnt/βcatenin pathway in murine PTEN/p53-deficient GEMM-derived SC1 cells.Supplementary Figure S17. Feedback Wnt/β-catenin-pathway activation within murine PTEN/p53-deficient GEMM-derived PC cells following long-term ADT + copanlisib + aPD1 treatment suppresses phagocytosis via increased histone lactylation within bone marrow derived macrophages (BMDM).</p>" @default.
• W4376611430 created "2023-05-17" @default.
• W4376611430 creator A5006481328 @default.
• W4376611430 creator A5006555178 @default.
• W4376611430 creator A5014932117 @default.
• W4376611430 creator A5016000403 @default.
• W4376611430 creator A5026516999 @default.
• W4376611430 creator A5038076681 @default.
• W4376611430 creator A5049507860 @default.
• W4376611430 creator A5049543850 @default.
• W4376611430 creator A5052468195 @default.
• W4376611430 creator A5057608003 @default.
• W4376611430 creator A5061774893 @default.
• W4376611430 creator A5065881608 @default.
• W4376611430 creator A5068014441 @default.
• W4376611430 creator A5068814417 @default.
• W4376611430 creator A5073680897 @default.
• W4376611430 creator A5075152000 @default.
• W4376611430 creator A5081681820 @default.
• W4376611430 creator A5081791257 @default.
• W4376611430 creator A5082246777 @default.
• W4376611430 creator A5082558529 @default.
• W4376611430 creator A5085739244 @default.
• W4376611430 creator A5086185350 @default.
• W4376611430 creator A5088797237 @default.
• W4376611430 creator A5089826782 @default.
• W4376611430 date "2023-05-15" @default.
• W4376611430 modified "2023-10-16" @default.
• W4376611430 title "Supplementary Figures S1-S17 from Reversal of Lactate and PD-1–mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-deficient Prostate Cancer" @default.
• W4376611430 doi "https://doi.org/10.1158/1078-0432.22820230.v1" @default.
• W4376611430 hasPublicationYear "2023" @default.
• W4376611430 type Work @default.
• W4376611430 citedByCount "0" @default.
• W4376611430 crossrefType "posted-content" @default.
• W4376611430 hasAuthorship W4376611430A5006481328 @default.
• W4376611430 hasAuthorship W4376611430A5006555178 @default.
• W4376611430 hasAuthorship W4376611430A5014932117 @default.
• W4376611430 hasAuthorship W4376611430A5016000403 @default.
• W4376611430 hasAuthorship W4376611430A5026516999 @default.
• W4376611430 hasAuthorship W4376611430A5038076681 @default.
• W4376611430 hasAuthorship W4376611430A5049507860 @default.
• W4376611430 hasAuthorship W4376611430A5049543850 @default.
• W4376611430 hasAuthorship W4376611430A5052468195 @default.
• W4376611430 hasAuthorship W4376611430A5057608003 @default.
• W4376611430 hasAuthorship W4376611430A5061774893 @default.
• W4376611430 hasAuthorship W4376611430A5065881608 @default.
• W4376611430 hasAuthorship W4376611430A5068014441 @default.
• W4376611430 hasAuthorship W4376611430A5068814417 @default.
• W4376611430 hasAuthorship W4376611430A5073680897 @default.
• W4376611430 hasAuthorship W4376611430A5075152000 @default.
• W4376611430 hasAuthorship W4376611430A5081681820 @default.
• W4376611430 hasAuthorship W4376611430A5081791257 @default.
• W4376611430 hasAuthorship W4376611430A5082246777 @default.
• W4376611430 hasAuthorship W4376611430A5082558529 @default.
• W4376611430 hasAuthorship W4376611430A5085739244 @default.
• W4376611430 hasAuthorship W4376611430A5086185350 @default.
• W4376611430 hasAuthorship W4376611430A5088797237 @default.
• W4376611430 hasAuthorship W4376611430A5089826782 @default.
• W4376611430 hasBestOaLocation W43766114301 @default.
• W4376611430 hasConcept C121608353 @default.
• W4376611430 hasConcept C126322002 @default.
• W4376611430 hasConcept C185592680 @default.
• W4376611430 hasConcept C190283241 @default.
• W4376611430 hasConcept C2777609662 @default.
• W4376611430 hasConcept C2777899217 @default.
• W4376611430 hasConcept C2777911890 @default.
• W4376611430 hasConcept C2780192828 @default.
• W4376611430 hasConcept C2780940892 @default.
• W4376611430 hasConcept C502942594 @default.
• W4376611430 hasConcept C55493867 @default.
• W4376611430 hasConcept C61367390 @default.
• W4376611430 hasConcept C71315377 @default.
• W4376611430 hasConcept C71924100 @default.
• W4376611430 hasConcept C86554907 @default.
• W4376611430 hasConcept C86803240 @default.
• W4376611430 hasConceptScore W4376611430C121608353 @default.
• W4376611430 hasConceptScore W4376611430C126322002 @default.
• W4376611430 hasConceptScore W4376611430C185592680 @default.
• W4376611430 hasConceptScore W4376611430C190283241 @default.
• W4376611430 hasConceptScore W4376611430C2777609662 @default.
• W4376611430 hasConceptScore W4376611430C2777899217 @default.
• W4376611430 hasConceptScore W4376611430C2777911890 @default.
• W4376611430 hasConceptScore W4376611430C2780192828 @default.
• W4376611430 hasConceptScore W4376611430C2780940892 @default.
• W4376611430 hasConceptScore W4376611430C502942594 @default.
• W4376611430 hasConceptScore W4376611430C55493867 @default.
• W4376611430 hasConceptScore W4376611430C61367390 @default.
• W4376611430 hasConceptScore W4376611430C71315377 @default.
• W4376611430 hasConceptScore W4376611430C71924100 @default.
• W4376611430 hasConceptScore W4376611430C86554907 @default.
• W4376611430 hasConceptScore W4376611430C86803240 @default.
• W4376611430 hasLocation W43766114301 @default.
• W4376611430 hasLocation W43766114302 @default.
• W4376611430 hasOpenAccess W4376611430 @default.
• W4376611430 hasPrimaryLocation W43766114301 @default.
• W4376611430 hasRelatedWork W2023591758 @default.
• W4376611430 hasRelatedWork W2037885504 @default.
• W4376611430 hasRelatedWork W2092268174 @default.
• W4376611430 hasRelatedWork W2415458772 @default.
• W4376611430 hasRelatedWork W2488918559 @default.

• next